16:02 EDT Neurocrine (NBIX) backs FY25 INGREZZA net product sales view $2.5B-$2.55B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ New Study on MDD Treatment: What Investors Need to Know
- Neurocrine Biosciences Advances Pediatric CAH Treatment with New Study
- NBIX Upcoming Earnings Report: What to Expect?
- Strong Buy Rating for Neurocrine Due to Robust Pipeline and Strategic Growth Potential
- Neurocrine initiated with a Buy at Citi